05:57:04 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Gravis Energy Corp
Symbol GVE
Shares Issued 39,129,960
Close 2017-02-17 C$ 0.005
Market Cap C$ 195,650
Recent Sedar Documents

Gravis merger deal did not include Toban, says Lee

2017-05-30 10:30 ET - Street Wire

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Mike Caswell

Jai Woo Lee, one of those linked to Gravis Energy Corp.'s recent merger agreement, says that there is no fee payable to former Vancouver broker Stephen Toban on the deal. Mr. Toban's role with the transaction was either non-existent or was insufficient to justify the $419,887 (U.S.) fee he is seeking, Mr. Lee claims. He further says that there was no agreement for Mr. Toban to receive any payment.

The statements come in response to a lawsuit that Mr. Toban filed in the Supreme Court of British Columbia on April 18, 2017. He claimed to have arranged a deal in which Gravis will merge with a Korean pharmaceutical company called Biocurepharm Corp. The deal will see Gravis change its business from mining and roll back 1:7. The defendants in the case are Mr. Lee and his company, Columbia Capital Inc.

Mr. Lee filed his response to the lawsuit on May 15, 2017. The brief document contains few details. In what information Mr. Lee has provided, he says that there was no agreement in place with Mr. Toban. He also says that it was not Mr. Toban who identified Biocurepharm as a suitable candidate for the merger, nor was it Mr. Toban who "brought in" Biocurepharm. (The response does not say who arranged the deal or even if Mr. Lee had a part in it.)

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2024 Canjex Publishing Ltd. All rights reserved.


Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.


Comments for this item are closed